National Research Development Corporation

Link copied
Case Copied 15 min read

official notice

decision of a delegate of the commissioner of patents

Application        :    No. 59784/90  in the name of NATIONAL RESEARCH DEVELOPMENT CORPORATION

Title:    Anxiolytic compositions containing Dioxopiperidine derivatives

Action:    Objection by the Commissioner during examination

Decision:    Issued            .  Description and claims found to have fundamental discrepancies so that section 40 not complied with. Claims specifying a particular quantity of a known pharmaceutical found to be not novel.

patents act 1990

decision of a delegate of the commissioner of patents

Re:Patent Application No. 59784/90 by NATIONAL RESEARCH DEVELOPMENT CORPORATION, and an objection by the Commissioner during examination.

background

Patent application 59784/90 was lodged on 24 July 1990 as a divisional application of application 602716. The earliest priority date that could be accorded the present application is that associated with 602716 - viz 8 September 1986.

The present application was lodged as a divisional application in response to certain objections raised during the examination of 602716. During the examination of the present application, those same objections were raised. The applicant requested a hearing, which was held in Melbourne on Feb 20 1992. The applicant was represented by Ms Elizabeth Eadie of Davies Collison Cave, Melbourne

specification

The specification of 59784/90 relates to the use of certain dioxopiperidines as anxiolytic drugs. It states that these dioxopiperidines have suprisingly been found to have strong anxiolytic activity. It refers to several prior art disclosures as follows:

-GB 1455687 (open for public inspection in Australia on 2 March 1977) discloses certain dioxopiperidines having use as antidepressants. The dose level is 0.1 to 100 mg/kg or 1 to 1000 mg per unit dose.

-US 4461771 (open for public inspection in Australia on 12 April 1985) discloses certain dioxopiperidines having use for treatment of migraine. The dose level is 0.01 to 10 mg/kg or 0.1 to 200 mg per unit dose.

-GB 2181346 (open for public inspection in Australia on 6 July 1987) discloses dioxopiperidine compositions which exhibit anxiolytic activity in the range of 0.1 to 20 mg/kg and hence pharmaceutical compositions containing 10 to 500 mg were proposed. GB 2181346 derives priority from GB 8621577 which is one of the basic documents of the parent application of the present case (although the present specification does not derive priority from GB 8621577).

The specification then states that "it has now suprisingly been found that the compounds are active at much lower dose levels, down to nanogram/kg amounts".

On page 10, the specification states:

"The amount of compound administered will vary and can be any anti-anxiety effective amount. Depending upon the patient and the mode of administration, the amount of compound administered may vary over a wide range to provide from about 10-7 to 10+2 mg/kg, usually 10-5 to 10+2 mg/kg, especially 10-4 to 10+2 mg/kg of body weight of the patient per unit dose. Unit doses in accordance with the invention can contain, for example, from about 10-6 mg to 10-2 mg, usually 10-4 to 10-2 mg, especially 10-3 to 10-2 mg of the…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read National Research Development Corporation and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[1992] APO 22
Decision Date

CaseChat Overview and Summary

The case concerns a patent application lodged by the National Research Development Corporation (NRDC) for anxiolytic compositions containing dioxopiperidine derivatives. The application, numbered 59784/90, was a divisional application of a previous application, 602716, and was lodged in response to objections raised during the examination of the earlier application. The Commissioner of Patents raised an objection during the examination of the new application, which led to a hearing in Melbourne on February 20, 1992. The applicant was represented by Ms Elizabeth Eadie of Davies Collison Cave.

The legal issues before the court were whether the claims in the patent application were novel, whether they complied with the requirements of section 40 of the Patents Act 1990, and whether the invention constituted a valid 'selection' patent. The court considered the prior art, the description and claims in the specification, and the arguments presented by Ms Eadie.

The court found that there were fundamental discrepancies between the description and the claims, and that the requirements of section 40 had not been complied with. The court noted that the specification implied human use of the invention, but the claims restricted the unit dose to less than 10^-2 mg, which was arbitrary and not based on the stated doses in the specification. Furthermore, the examples in the specification illustrated the use of doses much greater than that claimed. The court also found that the invention was not novel, as the difference from the prior art did not come about as a feature essential for the performance of the invention. Finally, the court concluded that the invention did not constitute a valid'selection' patent, as the beneficial properties associated with the invention were related to low administered doses, not low unit dosages.

As a result of these findings, the court allowed the applicant to propose further amendments to the description and claims within the time allowed for acceptance of the application.

Orders

Orders of the court

Background

Background to the litigation

Evidence

Evidence Before The Court

Decision

Reasons for decision

Ratio Decidendi

Legal Principle Established